Testosterone Therapy for Hypogonadism Not Tied to Increased CV Risk
FRIDAY, June 10, 2022 -- For men with hypogonadism, testosterone therapy does not appear to increase short- to medium-term cardiovascular risk, according to a review published in the June issue of The Lancet Healthy Longevity.
Jemma Hudson, from the...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news